TherapeuticsMD (TXMD) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
TherapeuticsMD Expands Commercial and Business Development Leadership
November 3, 2016 4:08 PM EDT- Dawn Halkuff appointed Chief Commercial Officer -
- Yulii Bogatyrenko appointed Senior Vice President of Business Development -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced two new strategic hires: Dawn Halkuff as Chief Commercial Officer and Yulii Bogatyrenko as Senior Vice President of Business Development. Both executives bring womens health experience and relevant skills to the company in advance of the potential launch of its first bio-identical hormone... More
TherapeuticsMD Announces Third Quarter 2016 Financial Results
November 3, 2016 4:06 PM EDT- Topline phase 3 data for TX-001HR Replenish Trial on track for fourth quarter of 2016 -
- TX-004HR PDUFA target action date of May 7, 2017 -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced its third quarter financial results for the quarter ended September 30, 2016.
Third Quarter and Recent Developments
Announced acceptance of a New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for TX-004HR (conditionally-approved trade name... More